Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» sacituzumab govitecan
sacituzumab govitecan
Immunomedics' Triple-Negative Breast Cancer Trial Halted Early Due to Compelling Efficacy
BioSpace
Tue, 04/7/20 - 10:10 am
Immunomeedics
sacituzumab govitecan
clinical trials
breast cancer
triple negative breast cancer
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Troubled Immunomedics tries again at FDA after rejection
Fierce Biotech
Thu, 12/5/19 - 10:07 am
Immunomedics
IMMU-132
sacituzumab govitecan
FDA
metastatic triple-negative breast cancer
After FDA rejection, Immunomedics tries again with breast cancer drug
Biopharma Dive
Tue, 12/3/19 - 10:23 pm
Immunomedics
breast cancer
sacituzumab govitecan
metastatic triple-negative breast cancer
FDA
2 Biotechs With Approaching Drug Approvals
Motley Fool
Sun, 10/13/19 - 11:30 pm
drug approvals
drug launches
FDA
voxelotor
Global Blood Therapeutics
Immunomedics
sacituzumab govitecan
With Immunomedics ADC deal, Everest bolsters cancer pipeline
BioCentury
Mon, 04/29/19 - 08:50 pm
Immunomedics
sacituzumab govitecan
Everest Medicines
Asia
FDA uncovers data manipulation at Immunomedics plant making cancer drug
Fierce Pharma
Thu, 02/14/19 - 10:02 am
FDS
Immunomedics
sacituzumab govitecan
drug manufacturing
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Biopharma Dive
Sat, 02/9/19 - 12:14 am
Immunomedics
FDA
sacituzumab govitecan
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Stat
Fri, 01/18/19 - 12:12 am
Immunomedics
FDA
breast cancer
sacituzumab govitecan
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Wed, 07/18/18 - 09:29 am
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Motley Fool
Mon, 06/4/18 - 10:09 pm
Immunomedics
ASCO 2018
sacituzumab govitecan
breast cancer
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
Mon, 06/1/15 - 10:06 am
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Yahoo
Mon, 04/20/15 - 05:15 pm
Immunomedics
chemotherapy
breast cancer
lung cancer
esophageal cancer
colorectal cancer
sacituzumab govitecan